Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
sargramostim · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| sargramostim | BIOLOGICAL | - |
| cyclophosphamide | DRUG | - |
| prednisone | DRUG | - |
| vincristine sulfate | DRUG | - |
DISEASE CHARACTERISTICS: Histologically proven multiple myeloma Pancytopenia related to multiple myeloma allowed Failed or progressed after at least 2 chemotherapy or biologic therapy regimens PATIENT CHARACTERISTICS: Age: 16 and over Performance status: Not specified Life expectancy: Not specified...
Sargramostim is being studied for use in multiple myeloma and plasma cell neoplasm. It is an investigational monoclonal antibody in Phase 2 clinical development. The drug is being evaluated in combination with chemotherapy for treating patients with multiple myeloma.
Sargramostim is being developed by Community Health Systems, Inc., which trades under the ticker CYH. The company is conducting clinical research on this investigational monoclonal antibody for oncology applications.
Sargramostim is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. The drug is being studied for the treatment of multiple myeloma and plasma cell neoplasm.
Sargramostim has one completed clinical trial, NCT00003490, titled 'Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma.' This Phase 2 study enrolled 30 participants in the United States and was not randomized or blinded.
Sargramostim is a monoclonal antibody, which means it is designed to bind to specific targets involved in disease. However, its exact molecular target has not been specified in the available information.
Sargramostim is not the same as GM-CSF. The clinical trial NCT00003490 evaluates combination chemotherapy following GM-CSF, indicating that GM-CSF is a separate agent used in the treatment regimen alongside sargramostim.